Ken Zeidner

Ken Zeidner has a diverse work experience in the pharmaceutical industry, specializing in intellectual property litigation and strategy. Ken is currently serving as the VP and Head of IP Litigation at Alembic Pharmaceuticals Limited since March 2019. Prior to this, Ken worked at Amneal Pharmaceuticals as the Vice President, responsible for setting the IP strategy for generic and 505(b)(2) filings. Before their tenure at Amneal, they worked as a Patent Attorney at Diehl Servilla LLC. Ken has also held positions as an Attorney at Budd Larner, Member at Norton Diehl LLP, Attorney at Lerner David Littenberg Krumholz & Mentlik, and Attorney at Fitzpatrick, Cella, Harper & Scinto.

Ken Zeidner's education history includes a Bachelor of Arts (B.A.) in Biological Sciences from Rutgers University, which they obtained from 1984 to 1989. Ken then pursued a Master of Science (M.S.) in Biological Sciences at James Madison University from 1989 to 1991. Following that, they completed a Ph.D. in Molecular and Medical Genetics from the Icahn School of Medicine at Mount Sinai, where they studied from 1991 to 1998. Finally, they attended Cardozo School of Law from 1998 to 2001, earning a Juris Doctor (J.D.) degree.